Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Stock Information for COMPASS Pathways Plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About COMPASS Pathways Plc

Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities
Compass Pathways to Announce First Quarter Financial Results on May 8, 2025
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.